Establishment Labs (NASDAQ:ESTA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Monday.
According to Zacks, “Establishment Labs Holdings Inc. is a medical technology company. It focuses on designing, developing, manufacturing and marketing portfolio of silicone gel-filled breast implants ae well as body shaping implants. The company’s brand consists of Motiva Implants(R) and MotivaImagine (R) platform. Its technologies portfolio includes Divina 3D Simulation System(R), Puregraft and MotivaImagine Centers (R). Establishment Labs Holdings Inc. is based in NEW YORK. “
ESTA has been the subject of several other research reports. Jefferies Financial Group initiated coverage on Establishment Labs in a research report on Monday, August 13th. They issued a “buy” rating and a $35.00 target price for the company. Cowen initiated coverage on Establishment Labs in a research report on Monday, August 13th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, BTIG Research initiated coverage on Establishment Labs in a research report on Monday, August 13th. They issued a “buy” rating and a $35.00 target price for the company.
Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.15. The business had revenue of $13.71 million for the quarter, compared to the consensus estimate of $12.10 million. Equities research analysts forecast that Establishment Labs will post -1.66 EPS for the current fiscal year.
About Establishment Labs
Establishment Labs Holdings Inc, a medical technology company, designs, develops, manufactures, and markets medical devices for aesthetic plastic surgery, reconstructive plastic surgery, and aesthetic dermatology. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name.
Further Reading: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.